ICD-10 Code C94.22 | Acute megakaryoblastic leukemia, in relapse Symptoms, Diagnosis, Billing

Acute megakaryoblastic leukemia, in relapse is a hematological malignancy characterized by the proliferation of megakaryoblasts in the bone marrow. This condition is clinically significant as it often presents with severe thrombocytopenia, leading to increased bleeding risk. Accurate coding with ICD-10 Code C94.22 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively manage and treat affected patients.

What is ICD-10 Code C94.22 for Acute megakaryoblastic leukemia, in relapse?

ICD-10 Code C94.22 represents Acute megakaryoblastic leukemia, in relapse, a subtype of acute myeloid leukemia characterized by the presence of immature megakaryocytes in the bone marrow. This code should be used when documenting a relapse of the disease, indicating a return of symptoms after a period of remission. Proper use of this code in clinical documentation and billing is crucial for accurate patient care and reimbursement.

ICD-10 Code C94.22 – Clinical Definition and Explanation of Acute megakaryoblastic leukemia, in relapse

Acute megakaryoblastic leukemia, in relapse, is caused by genetic mutations leading to the uncontrolled proliferation of megakaryoblasts. The condition can progress rapidly, resulting in severe complications such as bleeding and infection, necessitating immediate medical intervention.

Key Clinical Features:

• Presence of immature megakaryoblasts in the bone marrow.
• Severe thrombocytopenia leading to increased bleeding risk.
• Symptoms may include fatigue, pallor, and petechiae.
• Higher incidence in children, particularly those with Down syndrome.

ICD-10 Code C94.22 for Acute megakaryoblastic leukemia, in relapse – SOAP Notes & Clinical Use

ICD-10 Code C94.22 is utilized in SOAP notes to document the patient's symptoms, assessment findings, and treatment plans. This code is relevant in both acute and chronic care settings, ensuring comprehensive documentation of the patient's condition and facilitating appropriate management strategies.

What Does ICD-10 Code C94.22 for Acute megakaryoblastic leukemia, in relapse Mean in SOAP Notes?

In SOAP notes, ICD-10 Code C94.22 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Acute megakaryoblastic leukemia, in relapse. This ensures continuity of care, supports accurate billing, and meets EHR documentation standards.

Treatment Options for ICD-10 Code C94.22 – Acute megakaryoblastic leukemia, in relapse

Acute megakaryoblastic leukemia, in relapse, requires urgent medical treatment, often necessitating hospitalization for intensive care.

Antibiotic Therapy:

• Cefepime: First-line for febrile neutropenia, typically 7-14 days.
• Piperacillin-tazobactam: Alternative for broad-spectrum coverage, 7-14 days.
• Meropenem: Considered for resistant infections, duration based on clinical response.

Supportive Care:

• Transfusion of platelets and red blood cells as needed.
• Administration of growth factors to stimulate blood cell production.
• Management of complications such as infections and bleeding.

Infection Control:

• Strict hand hygiene and use of personal protective equipment (PPE).
• Isolation precautions for neutropenic patients.
• Monitoring for signs of infection and prompt intervention.

How to Document Symptoms of Acute megakaryoblastic leukemia, in relapse (ICD-10 C94.22) in SOAP Notes

Subjective:

• Patient reports increased fatigue and weakness.
• History of easy bruising and frequent nosebleeds.
• Complaints of fever and chills over the past week.
• Previous remission of leukemia with recent symptom recurrence.

Objective:

• Pallor noted on physical examination.
• Platelet count significantly low on CBC.
• Bone marrow biopsy shows >20% megakaryoblasts.
• Vital signs: Temperature 101°F, heart rate 110 bpm.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Acute megakaryoblastic leukemia, in relapse (ICD-10 Code C94.22)

Assessment:

• Diagnosis: Acute megakaryoblastic leukemia, in relapse, severe.
• ICD-10 Code: C94.22.
• Contributing factors: Previous treatment history and genetic predisposition.
• Symptoms consistent with relapse of leukemia.

Plan:

• Initiate chemotherapy regimen as per protocol.
• Administer supportive care including transfusions.
• Educate patient on signs of infection and bleeding.
• Schedule follow-up appointments for monitoring response to treatment.

Treatment & Plan Section for ICD-10 Code C94.22 – Acute megakaryoblastic leukemia, in relapse

• First-line treatment includes intensive chemotherapy.
• Consideration for stem cell transplant based on patient eligibility.
• Regular monitoring of blood counts and clinical status.
• Patient education on managing side effects and recognizing complications.

Using ICD-10 Code C94.22 for Acute megakaryoblastic leukemia, in relapse in Billing & SOAP Note Compliance

• Ensure accurate documentation of symptoms and clinical findings.
• Use C94.22 in conjunction with relevant procedure codes for billing.
• Maintain compliance with coding guidelines to support reimbursement.
• Document treatment plans that align with clinical guidelines.

Related ICD-10 Codes Often Used with Acute megakaryoblastic leukemia, in relapse

• C94.21 – Acute megakaryoblastic leukemia, not in relapse
• C92.40 – Acute myeloid leukemia, unspecified
• C92.41 – Acute myeloid leukemia, in remission
• C93.00 – Acute lymphoblastic leukemia, unspecified

ICD-10 Code C94.22 in Medical Billing and Insurance for Acute megakaryoblastic leukemia, in relapse

ICD-10 Code C94.22 is critical for accurate billing in hospital, ER, or infectious disease care settings.

Billing Notes:

• Document all relevant clinical findings to support the diagnosis.
• Use C94.22 in appropriate settings to ensure proper reimbursement.
• Include detailed treatment plans and patient education in documentation.
• Ensure compliance with payer requirements for coding and billing.

Common CPT Pairings: